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Effect of restrictive versus liberal transfusion strategies 
on outcomes in patients with cardiovascular disease  
in a non-cardiac surgery setting: systematic review and 
meta-analysis
Annemarie B Docherty,1, 2 Rob O’Donnell,2 Susan Brunskill,3 Marialena Trivella,3 Carolyn Doree,4 
Lars Holst,5 Martyn Parker,6 Merete Gregersen,7 Juliano Pinheiro de Almeida,8 Timothy S Walsh,1, 2 
Simon J Stanworth3 , 9 
ABSTRACT
ObjeCtive
To compare patient outcomes of restrictive versus 
liberal blood transfusion strategies in patients with 
cardiovascular disease not undergoing cardiac 
surgery.
Design
Systematic review and meta-analysis.
Data sOurCes
Randomised controlled trials involving a threshold for 
red blood cell transfusion in hospital. We searched (to 
2 November 2015) CENTRAL, Medline, Embase, 
CINAHL, PubMed, LILACS, NHSBT Transfusion Evidence 
Library, ClinicalTrials.gov, WHO International Clinical 
Trials Registry Platform, ISRCTN Register, and EU 
Clinical Trials Register. Authors were contacted for data 
whenever possible.
trial seleCtiOn
Published and unpublished randomised controlled 
trials comparing a restrictive with liberal transfusion 
threshold and that included patients with 
cardiovascular disease.
Data extraCtiOn anD synthesis
Data extraction was completed in duplicate. Risk of 
bias was assessed using Cochrane methods. Relative 
risk ratios with 95% confidence intervals were 
presented in all meta-analyses. Mantel-Haenszel 
random effects models were used to pool risk ratios.
Main OutCOMe Measures
30 day mortality, and cardiovascular events.
results
41 trials were identified; of these, seven included data 
on patients with cardiovascular disease. Data from a 
further four trials enrolling patients with cardiovascular 
disease were obtained from the authors. In total, 11 
trials enrolling patients with cardiovascular disease 
(n=3033) were included for meta-analysis (restrictive 
transfusion, n=1514 patients; liberal transfusion, 
n=1519). The pooled risk ratio for the association 
between transfusion thresholds and 30 day mortality 
was 1.15 (95% confidence interval 0.88 to 1.50, 
P=0.50), with little heterogeneity (I2=14%). The risk of 
acute coronary syndrome in patients managed with 
restrictive compared with liberal transfusion was 
increased (nine trials; risk ratio 1.78, 95% confidence 
interval 1.18 to 2.70, P=0.01, I2=0%).
COnClusiOns
The results show that it may not be safe to use a 
restrictive transfusion threshold of less than 80 g/L in 
patients with ongoing acute coronary syndrome or 
chronic cardiovascular disease. Effects on mortality 
and other outcomes are uncertain. These data support 
the use of a more liberal transfusion threshold (>80 
g/L) for patients with both acute and chronic 
cardiovascular disease until adequately powered high 
quality randomised trials have been undertaken in 
patients with cardiovascular disease.
registratiOn
PROSPERO CRD42014014251.
Introduction
Approximately seven million people in the United King-
dom have cardiovascular disease,1  and it is a prevalent 
comorbidity among patients admitted to hospital. In 
observational studies, anaemia is associated with 
worse outcomes in patients who have both acute and 
chronic cardiovascular disease, but it is unclear 
whether this association is causal or whether correction 
with red blood cell transfusions modifies this rela-
tion.2-5  Anaemia decreases the oxygen content of the 
blood supplied to the myocardium and may increase 
myocardial oxygen demand because a higher cardiac 
output is required to maintain adequate systemic oxy-
gen delivery.6  The heart extracts a high proportion of 
the oxygen supplied through the coronary arteries, and 
therefore this circulation is potentially at higher risk 
WhAT IS AlReAdy knoWn on ThIS TopIC
Restrictive red cell transfusion policies are recommended as safe for most hospital 
patients with anaemia
Uncertainty exists for patients with cardiovascular disease, whose hearts may be 
more susceptible to limited coronary oxygen supply
No systematic reviews have specifically compared outcomes for patients with 
cardiovascular disease in a non-cardiac surgery setting, and guidelines 
acknowledge the paucity of evidence in this area
WhAT ThIS STudy AddS
Restrictive blood transfusion strategies may not be as safe as more liberal strategies 
for patients with coexisting cardiovascular disease in non-cardiac surgery settings
An increased risk of acute coronary syndrome was shown with restrictive thresholds 
(haemoglobin level <80 g/L)
These data support the use of a more liberal transfusion threshold (>80 g/L) for 
patients with both acute and chronic cardiovascular disease, until adequately powered 
high quality randomised trials have been undertaken in this patient  population
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from the combination of atheroma related flow limita-
tion and anaemia. Hypotension, tachycardia, and the 
requirement for catecholamine use (for example, 
during critical illness or major surgery) can further 
compromise the balance between oxygen supply and 
demand, resulting in myocardial injury. This has been 
termed type 2 myocardial infarction.7  The release of tro-
ponin, a biomarker of myocardial injury, is associated 
with higher mortality in critically ill and perioperative 
populations.8-10
Systematic reviews of randomised trials of liberal ver-
sus restrictive blood transfusion strategies support a 
general default trigger threshold for haemoglobin levels 
of around 70 g/L for most patient groups,11-13  and this is 
reflected in recent guidelines advocating restrictive use 
of blood transfusions.14-17  These guidelines have high-
lighted the lack of evidence and uncertainty about best 
practice for patients with acute or chronic cardiovascu-
lar disease.14-17  No systematic reviews have specifically 
compared outcomes for patients with chronic cardiovas-
cular disease undergoing non-cardiac surgery, or other 
treatments such as intensive care. A recent systematic 
review restricted to patients undergoing cardiac surgery 
suggested better outcomes with more liberal transfu-
sions, highlighting the potentially important interaction 
between anaemia, blood transfusions, and outcomes for 
patients with cardiovascular disease.18  The National 
Institute for Health and Care Excellence guideline on 
blood transfusion, published in November 2015, stated 
that the optimal transfusion threshold for patients with 
ongoing acute coronary syndrome was 80-100 g/L, but it 
made no specific recommendation for patients with 
chronic cardiovascular disease and highlighted the 
need for further research in this specific population.19
We conducted a systematic review and meta-analysis 
assessing the effect of restrictive versus liberal red cell 
transfusion strategies on patient outcomes restricted to 
adults with cardiovascular disease, excluding those 
who had cardiac surgery.
Methods
This systematic review was conducted according to the 
protocol registered with PROSPERO. We followed meth-
ods defined in the preferred reporting items for system-
atic reviews and meta-analyses statement.20
eligibility criteria
We included only randomised controlled trials. Trials 
were eligible for inclusion if they evaluated the effec-
tiveness of any policy involving the use of a trigger or 
transfusion threshold based on haemoglobin concen-
tration (including haematocrit) for guiding allogeneic 
red cell transfusion. Control group patients were 
required to receive transfusion at a higher haemoglobin 
concentration or haematocrit. We considered trials 
including adults (≥18 years) except those who had 
undergone cardiac surgery as this is a distinct group of 
patients with a clinically significantly altered cardio-
vascular risk as a result of the procedure.21 We excluded 
children and neonates owing to the low prevalence of 
cardiovascular disease.
In our protocol we defined cardiovascular disease as 
known coronary artery disease (acute coronary syn-
drome, chronic ischaemic heart disease) or other car-
diovascular disease (cerebrovascular accident, 
transient ischaemic attack, peripheral vascular dis-
ease). We defined acute coronary syndrome as ST eleva-
tion myocardial infarction, non-ST elevation myocardial 
infarction, or unstable angina. Supplementary table E1 
summarises the definitions for cardiovascular disease 
used by the authors of included trials.
search strategy
We did not restrict our search by language, date, or pub-
lication status. We updated a search strategy we con-
ducted in September 2009, reviewing the overall use of 
red blood cell transfusions.22 The present search 
included two changes: in CENTRAL there was a date 
restriction, and in Medline and Embase the following 
search method was used: the original search 
 strategies+original randomised controlled trial filters 
were rerun up until the end of 2008; the new strate-
gies+new randomised controlled trial filters were run 
for all years; the results of rerunning the original search 
strategies+original randomised controlled trial filter 
until 2009 were then removed from the new search 
results. Once all the search results had been down-
loaded into bibliographic software, we removed all pre-
viously screened references from the overview of the 
use of red blood cell transfusion, along with any dupli-
cates. The search strategies are available in the online 
data supplement.
The date of the last search was 2 November 2015 for 
the following databases: CENTRAL (Cochrane Library 
issue 8, 2014): publication years 2009-14; Medline (1946 
onwards); Embase (1974 onwards); CINAHL (1937 
onwards); PubMed (epublications only); LILACS (2009-
14); Transfusion Evidence Library (1980 onwards); and 
Web of Science (Conference Proceedings Citation 
Index-Science, 1990 to present).
We searched for ongoing studies in five registries: 
ClinicalTrials.gov, WHO international clinical trials reg-
istry platform, ISRCTN register, European Union clini-
cal trials register (www.clinicaltrialsregister.eu/
ctr-search), and the Hong Kong clinical trials registry. 
All sites were searched on 2 November 2015. Supple-
mentary appendix 1 details the search strategies.
Data extraction
Trial selection
Two authors (AD and RO) independently reviewed all 
identified titles and abstracts against the prespecified 
eligibility criteria. Disagreements were resolved by dis-
cussion with the other authors. We considered all pub-
lications reporting a randomised controlled trial that 
used a valid transfusion threshold and where inclusion 
criteria indicated patients with cardiovascular disease. 
We contacted the authors of eligible trials that included 
cardiovascular subgroups or a high proportion of 
patients with cardiovascular disease and requested 
data for these patients. For trials that included patients 
both with and without cardiovascular disease, we 
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ascertained whether randomisation was stratified by 
the presence or absence of cardiovascular disease.
Data were extracted using a form piloted before the 
study. Two authors (AD and RO) independently 
extracted data on trial characteristics, primary and sec-
ondary outcomes, cardiac specific morbidity, and gen-
eral morbidity. A third author (SS) checked for 
discrepancies between the independent data 
extraction, and disagreements were resolved by discus-
sion between the three authors. Our primary outcome 
was mortality at 30 days. We also extracted mortality 
data at 60 days, mortality during intensive care unit or 
hospital stay, and other mortality as defined by the 
authors.
Wherever possible we categorised data on cardiovas-
cular events as acute coronary syndrome, acute pulmo-
nary oedema, peripheral ischaemia, and thrombotic 
events. The category of acute coronary syndrome 
included myocardial infarction, acute coronary syn-
drome, and cardiac arrest.
Measures of general morbidity were use of packed 
red blood cells, adverse reactions to transfusion, inci-
dence of in-hospital infections, measures of organ dys-
function, duration of intensive care unit or hospital 
stay, invasive ventilation, haemodynamic support, and 
renal support.
risk of bias assessment
We assessed the risk of bias using the method outlined 
in the Cochrane Collaboration Handbook for Systematic 
Reviews of Interventions.23 Risk of bias was assessed as 
high, low, and unclear for each of selection bias, perfor-
mance bias, detection bias, attrition bias, and reporting 
bias. We specifically assessed blinding for the outcomes 
of cardiovascular events.
grading quality of evidence
We assessed the quality of evidence for mortality, acute 
coronary syndrome, and acute pulmonary oedema 
according to GRADE methods for risk of bias, inconsis-
tency, indirectness, imprecision, and publication bias. 
These were classified as very low, low, moderate, or 
high.24
Data synthesis and analysis
All statistical analyses were performed using Review 
Manager 5.25 Meta-analysis was undertaken where data 
were sufficient. We used a random effect model as we 
anticipated that there would be substantial clinical het-
erogeneity. We reported relative risk ratios for dichoto-
mous outcomes, with 95% confidence intervals. Median 
and interquartile ranges described non-parametric 
measures.
We included one cluster randomised trial.26 However, 
we had no information on which clusters the patients 
with cardiovascular disease were in, and the intraclass 
correlation coefficient was 0.001 for mortality, suggest-
ing that only 0.1% of the variance was due to the effect 
of the trial site and 99.1% to differences between 
patients. We performed a sensitivity analysis without 
taking the clustering into account, and this did not 
alter our results. These data were therefore included as 
unique patient data.
assessment of heterogeneity
Assessment of clinical heterogeneity included consider-
ation of participant characteristics (eg, acute coronary 
syndrome versus chronic cardiovascular disease) and 
the clinical setting (critical care versus orthopaedics 
versus acute coronary syndrome). We undertook a sub-
group analysis of patients with chronic cardiovascular 
disease, excluding trials including patients with ongo-
ing acute coronary syndromes. Data were insufficient to 
undertake the preplanned subgroup analyses of critical 
care trials or of acute coronary syndromes.
We assessed statistical heterogeneity of treatment 
effects between trials using the χ2 test. The I2 statistic 
was used to quantify the percentage of variability that 
was due to heterogeneity (we defined heterogeneity of 
>50% as moderate and >80% as substantial).
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
the design and implementation of the study. There are 
no plans to involve patients in the dissemination of the 
results.
Results
search results
Figure 1  shows the flow of studies through the review. 
The search retrieved 9462 results (of which 283 were 
ongoing randomised controlled trials), which were 
reduced to 6520 results once duplicates were removed. 
After removal of previously screened references, 3955 
titles and abstracts (3832 completed trials and 123  ongoing 
Records aer duplicates removed (n=6520)
Full text assessed for eligibility (n=41)
Trials in quantitative analysis (n=11)
Records screened (n=3832)
Plus ongoing trials (n=123)
Additional records (n=1)Records identied through
database searching (n=9462)
Excluded (n=30):
  Abstracts only (n=8)
  Full text excluded (n=22):
    No reply from authors (n=7)
    Excluded CVD (n=6)
    CVD not baseline characteristic (n=7)
    Sickle cell trial (n=2)
Records excluded (n=3795)
Ongoing trials (n=123)
No data on patients with cardiovascular
disease available (n=30)
Previously screened texts (n=2565)
Fig 1 | PrisMa flow diagram. CvD=cardiovascular disease
doi: 10.1136/bmj.i1351 | BMJ 2016;352:i1351 | the bmj
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randomised controlled trials) were screened for eligibil-
ity. Of these, 41 completed trials were eligible for full text 
screening (with five of the ongoing trials being poten-
tially eligible for inclusion on their completion).27-31
Thirty trials were ineligible for inclusion. Six 
excluded patients with signs or symptoms of heart dis-
ease, cardiac disease with New York Heart Association 
Class (NYHA) II or above, and American Society of 
Anesthetists class (ASA) II or worse.32-37  Two trials tar-
geted preoperative haemoglobin S levels in sickle cell 
anaemia and were therefore not relevant.38 39  Seven full 
text trials40-46  and eight abstracts27 47-53 did not include 
cardiovascular disease as a baseline characteristic.
From the 41 potentially eligible trials, we were able to 
extract data on patients with cardiovascular disease 
from seven (n=2796).26 54-59  One of these trials published 
30 day mortality data for patients with cardiovascular 
disease, and the authors responded to our request for 
further data on cardiovascular outcomes and general 
morbidity outcomes (n=32).59  From reported baseline 
demographic data we were aware that patients with car-
diovascular disease were included in 11 further tri-
als,60-70  but we were unable to extract any relevant data 
directly from the published text. After contact with the 
authors for any data on patients with cardiovascular 
disease in their trials, we were able to include data from 
four trials.66-69  We did not contact the authors of the 
seven trials and eight abstracts that did not mention 
cardiovascular disease as a baseline characteristic in 
their trial.27 40-53 Characteristics of all 29 eligible trials 
that are not included in this review can be found in 
 supplementary table E1. In this review we included 
11 transfusion threshold trials involving patients with 
cardiovascular disease (n=3033).
trial characteristics
The setting of the 11 included trials varied: orthopaedics 
(n=3),55 66 69  upper gastrointestinal bleeding (n=1),26 
acute coronary syndrome or myocardial infarction 
(n=2),56 57  critical care (n=4),58 59 67 68  and elective aortic 
and infra-inguinal revascularisation (n=1).54
Definitions of cardiovascular disease differed 
between trials (see supplementary table E1). Other than 
one trial of elective aortic and infra-inguinal revascular-
isation,54  all trials included patients with a diagnosis of 
ischaemic heart disease, and all but the two acute myo-
cardial infarction trials56 57  included patients with con-
gestive cardiac failure. Other trials also included risk 
factors for ischaemic heart disease, including periph-
eral vascular disease,54 55 58 66 67 70  cerebrovascular 
 disease,55 66 67 68  diabetes,66  and hypertension.66  Trials 
varied from all patients having cardiovascular 
disease 54-57  to predefined cardiovascular disease sub-
groups,26 58 68  to high proportions of patients with car-
diovascular disease.59 66 67 69  Included trials were both 
multicentre (n=7)26 55-59 68  and single centre trials 
(n=4).54 66 67 69
Red cell transfusion thresholds varied. The lowest 
threshold for restrictive transfusion was 70 g/L (n=274, 
from four trials)58 59 67 68  to 80 g/L (n=1125, from three 
trials)26 55 56  and 90 g/L (n=50)54  to 97 g/L (n=34).69  In 
one trial transfusion was carried out only with symp-
toms of anaemia (n=55)66  and in another by haemato-
crit concentration (24%, n=24).57  Thresholds for liberal 
transfusion also varied considerably: the most common 
were 90 g/L (n=290, from four trials)58 59 67 68  and 100 g/L 
(n=1221 from five trials).26 54-56 66  Other thresholds were 
haemoglobin level 113 g/L (n=25)69  and 30% haemato-
crit (n=21).57  Six out of the 11 trials used leucocyte 
reduced red blood cells.55-57 59 68 69
Through data extraction, we were able to identify 
unique data for patients with cardiovascular disease for 
3033 participants from 11 trials. The sample sizes of 
these trials varied from 4557  to 2015.55  Of the 3033 
patients with cardiovascular disease, 1514 were ran-
domised to restrictive transfusion thresholds and 1519 
to liberal transfusion thresholds. Six trials that included 
patients both with and without cardiovascular disease 
did not stratify their randomisation by the presence or 
absence of cardiovascular disease.12 26 58 66 67 69 Table 1 
describes the characteristics of all included trials.
Comparison of exposure to transfusion strategy
Duration of intervention from randomisation—the dura-
tion of exposure to the two strategies varied consider-
ably. One trial maintained the haemoglobin threshold 
for one year post-randomisation,66  two trials for 30 
days,69 71  five trials until hospital discharge,26 54-57  three 
trials until discharge from intensive care,58 67 68  and one 
trial for up to 14 days.59
Exposure to allogenic blood—The requirements for 
red blood cell transfusion were extracted from six 
 trials54-57 59 66  (see supplementary table E3). For all six 
trials, patients in the restrictive transfusion arm were 
exposed to considerably less allogeneic blood than 
were patients in the liberal transfusion arm. In the 
restrictive transfusion arms, between 20.4%54  and 
84.2%66  of patients received no blood transfusions 
compared with a range of 0%57 66  to 12%54  for the liberal 
transfusion arms. Among patients who did receive red 
blood cells, the number of transfused units was lower in 
the restrictive transfusion arms (range from median 0 
(interquartile range 0-1)55  to a mean of 1.6 units (SD 
2.0))57  compared with the liberal transfusion arms 
(range from a mean of 1.58 units (SD 1.13)56  to a mean of 
2.5 units (SD 1.3)).57
effects on outcomes
Mortality
Data on mortality were available from all 11 trials. Thirty 
day mortality was given for all trials except one, which 
reported 28 day mortality.26 Overall, 144 deaths (9.5%) 
occurred in the restrictive transfusion arms compared 
with 126 (8%) in the liberal transfusion arms (pooled 
effect estimate: risk ratio 1.15, 95% confidence interval 
0.88 to 1.50, P=0.50, I2=14%, 3033 patients, fig 2 ). We 
performed a subgroup analysis, including only trials 
where the randomisation was stratified for cardiovascu-
lar disease,54-56 57 59 and for this subgroup the relative 
risk was 0.96 (95% confidence interval 0.58 to 1.59, 
P=0.87, I2=14%). The sensitivity analysis in which the 
two trials including patients with acute coronary 
the bmj | BMJ 2016;352:i1351 | doi: 10.1136/bmj.i1351
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 syndrome were excluded56 57  supported the result of the 
primary analysis (1.10, 0.88 to 1.37). The GRADE quality 
of evidence was judged to be moderate (table 2).
Two trials also presented mortality for all patients at 
60 days55 67  and three trials at 90 days66 68 69; however, 
we were only able to extract data on patients with car-
diovascular disease from one trial (60 day mortality: 
restrictive transfusion 66/1007 (6.6%) v liberal transfu-
sion 76/998 (7.6%)).55
Adverse events: cardiovascular
Nine trials presented data (2609 patients) on new car-
diovascular events.54-59 66-68  The definition of myocar-
dial infarction varied between trials (see supplementary 
table E4). All trials except two (definition unclear)58 66 
required electrocardiographic changes with an increase 
or decrease of cardiac biomarkers using the third uni-
versal definition of myocardial infarction.7  Five trials 
also required symptoms consistent with myocardial 
ischaemia.17 55 57 67 68  The diagnosis of myocardial infarc-
tion was made by investigators in four trials,55 56 67 68 
 clinicians in three trials,57 59 66  and was unclear in two 
trials.54 58  The diagnosis was blinded in four tri-
als,55 56 67 68  unblinded in three trials,57 59 66  and unclear 
in two trials.54 58  The incidence of acute coronary syn-
drome (fig 3 ) ranged from 0%66 67  to 20.4%56  in the 
restrictive transfusion arms and 0%57 59 66 67  to 11.1%56 in 
the liberal transfusion arms. There was evidence of an 
increased incidence of acute coronary syndrome in 
patients in the restrictive transfusion arms compared 
with patients in the liberal transfusion arms (risk ratio 
1.78, 95% confidence interval 1.18 to 2.70, P=0.01, I2=0%, 
restrictive transfusion: 59 events/1319 patients v liberal 
transfusion: 32 events/1290 patients). This corresponds 
to 4.6 episodes of acute coronary syndrome per 100 
patients when using restrictive strategies and 2.7 per 
100 patients when using liberal strategies. To prevent 
one episode of acute coronary syndrome, 52 patients 
would need to be treated with a liberal transfusion 
strategy.
For the analysis of patients with acute pulmonary 
oedema, three trials had a higher incidence of acute 
pulmonary oedema in the liberal transfusion arms,57 58 66 
whereas one trial had a higher incidence in the restric-
tive transfusion arm.56 There was no evidence of a dif-
ferent risk of acute pulmonary oedema in the restrictive 
transfusion arms compared with liberal transfusion 
arms (risk ratio 0.63, 95% confidence interval 0.22 to 
1.81, P=0.39, I2=60%, fig 3, restrictive: 24 events/309 
patients v liberal: 47 events/340 patients). Two trials 
reported no new episodes of acute pulmonary 
oedema,66 67  and there was only one episode of acute 
pulmonary oedema, in one trial.59 Cerebrovascular and 
thrombotic events were rare in both restrictive and lib-
eral transfusion arms and meta-analysis was not possible.
A sensitivity analysis excluding trials that did not 
stratify randomisation based on cardiovascular dis-
ease, had minimal impact on the estimates for the out-
comes of acute coronary syndrome and acute 
pulmonary oedema. The GRADE quality of evidence 
was judged low for acute coronary syndrome mainly 
because of the serious risk of bias in outcome assess-
ment (table 2 ). Sensitivity analysis excluding the two 
acute coronary syndrome trials56 57  had minimal impact 
table 1 | Characteristics of included trials contributing to data-analysis
trials Clinical setting
restrictive transfusion; liberal transfusion
Primary endpointthreshold
no of 
participants
no (%) of patients 
with CvD
Almeida 2013, Brazil (single 
centre)
Oncology 70 g/L; 90 g/L 101; 97 22 (21.8); 12 (12.4) Composite death or severe 
complications
Bush 1997, USA (single centre) Elective vascular 
surgery
90 g/L; 100 g/L 50; 49 50 (100); 49 (100) Myocardial ischaemia, myocardial 
infarction, death
Carson 2011, USA/Canada 
(multicentre)
Patients with hip 
fracture and with CVD 
or risk factors for CVD*
80 g/L or symptoms of 
anaemia; 100 g/L
1009; 1007 1009 (100); 1007 (100) 60 day mortality; walk unaided
Carson 2013, USA (multicentre) Symptomatic coronary 
artery disease*
8 g/dL or symptoms of 
anaemia; 10 g/dL
55; 55 55 (100); 55 (100) Composite: all cause mortality, 
myocardial infarction, or unscheduled 
coronary revascularisation
Cooper 2011, USA (multicentre) Acute myocardial 
infarction*
Haemotocrit: <24%; <30% 24; 21 24 (100); 21 (100) Composite: In-hospital death, 
recurrent myocardial infarction, new 
or worsening congestive heart failure
Gregersen 2015, Denmark  
(single centre)
Frail elderly patients 
with hip fracture*
97 g/L; 113 g/L 116; 111 34 (29.3); 25 (22.5) Recovery from physical disabilities
Hebert 1998, Canada (multicentre) Critical care 70 g/L; 90 g/L 418; 420 160 (38.2); 197 (46.9) 30 day mortality
Holst 2014, Scandinavia 
(multicentre)
Critical care* 70 g/L; 90 g/L 502; 496 75 (14.9); 66 (13.3) 90 day mortality
Jairath 2015, UK (multicentre) Upper gastrointestinal 
haemorrhage
80 g/L; 100 g/L 403; 533 61 (15%); 76 (14%) Feasibility
Parker 2013, UK (single centre) Patients with hip 
fracture
Definite symptoms of 
anaemia; raise haemoglobin 
level to at least 10.0 g/dL
100; 100 50 (50.0); 37 (37.0) 30 day mortality
Walsh 2013, UK (multicentre) Critical care* 70 g/L; L: 90 g/L 51; 49 17 (33.3); 15 (30.6) Feasibility: difference in mean 
haemoglobin concentration during 
intervention period
CVD=cardiovascular disease.
*Leucodepleted.
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on the point estimates for this outcome of new acute 
coronary syndrome (risk ratio 1.76, 1.10 to 2.81). The risk 
of acute coronary syndrome remained higher for the 
restrictive group on removal of the largest trial, which 
had 2016 participants (risk ratio 2.07, 1.02 to 4.23).55
Adverse events: general
Non-cardiovascular adverse events were reported 
across eight trials (see supplementary table E5).17 54 55 57-
59 66 69 These endpoints were described differently in 
each paper owing to the different clinical settings and 
rationale of the trials.
Six trials reported hospital length of stay for patients 
with cardiovascular disease.54-59 69  The difference 
between the restrictive and liberal transfusion arms 
was not significant (mean difference 1.24 days, 95% 
confidence interval −1.0 to 3.48, P=0.28, see supple-
mentary figure E2). Three trials reported in-hospital 
infection, but the number of events was small 
(see  supplementary table E2).56 66 71  One trial found no 
 differences in organ support in a retrospective analysis 
of patients with cardiovascular disease (L Holst, per-
sonal communication, 2016),68 and no events were clas-
sified as adverse transfusion reactions.
Risk of bias
The risk of bias is summarised in figures 2 and 3 . The 
main category for high risk of bias was the lack of 
blinding of participants, clinical staff, and research 
staff (identified in six trials).26 55 57-59 68  The diagnosis of 
cardiovascular events is difficult in many of the settings 
in which trials took place, such as during critical ill-
ness, increasing the risk of performance bias in con-
junction with unblinded outcome assessors. Another 
potential explanation for differing prevalence between 
trials was variations in definitions used (see supple-
mentary table E4). Cardiovascular events were diag-
nosed by investigators in five trials56-58 67 68  and 
All studies
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unblinded clinicians in three trials.57 59 66  The criteria for 
myocardial infarction were clearly defined in seven 
 trials54-57 59 67 68  and were unclear in two trials.58 66  In 
only one trial was both the definition and the outcome 
assessment at high risk of bias,66 but no new cardiovas-
cular events were diagnosed in this trial and its removal 
did not alter the analysis.
discussion
We identified data from 11 randomised trials that 
enrolled 3033 patients with cardiovascular disease in 
whom mortality data were available at 30 days, and 
nine trials that enrolled 2609 patients with cardio-
vascular disease in whom data on new cardiovascu-
lar events were available. A restrictive transfusion 
threshold was associated with an increased risk of 
acute coronary syndrome in patients with cardiovas-
cular disease, with low heterogeneity between trials 
(moderate quality of evidence as assessed by 
GRADE). We found no evidence of a difference in 30 
day mortality between restrictive and liberal transfu-
sion groups. The incidence of pulmonary oedema did 
not differ between the transfusion thresholds, but 
heterogeneity was present between trials and the 
GRADE quality of evidence was judged to be very low. 
The length of hospital stay did not differ between 
restrictive and liberal transfusion strategies, and 
other outcomes were rare, with inadequate data for 
meta-analysis.
This is the first systematic review to specifically deal 
with clinical outcomes for patients with acute and 
chronic cardiovascular disease managed with restric-
tive or liberal transfusions and not including patients 
undergoing cardiac surgery. Several well conducted 
systematic reviews have been published, but these did 
not examine patient subgroups with cardiovascular dis-
ease.11-13  The inclusion of heterogeneous populations in 
trials can mask potentially divergent effects in subpop-
ulations,72  and effects may be amplified when trials are 
combined for meta-analyses. The 2012 Cochrane review 
recommended the use of a restrictive transfusion trigger 
but suggested caution in patients from high risk groups 
such as those with acute coronary syndrome.13  Similar 
statements were made by Holst12  and Brunskill11  in 
their systematic reviews of transfusion thresholds for 
sepsis and patients undergoing surgery for hip fracture, 
respectively. Evidence is limited by the under-represen-
tation of patients with cardiovascular disease in many 
randomised controlled trials. For example, only 20% of 
patients enrolled in a large critical care trial had cardio-
vascular disease, compared with 29% of excluded 
patients.58  Similarly, only 14% of patients enrolled in a 
trial of septic shock had cardiovascular disease,68 
whereas observational trials suggest around 25-30% of 
critical care populations may have coexisting cardiac 
disease.8 73
The previous reviews in heterogeneous populations 
suggest overall trends towards lower 30 day mortality 
with restrictive transfusion strategies (range of risk 
ratio 0.85, 95% confidence interval 0.70 to 1.0313  to 0.92, 
0.67 to 1.26),11  whereas the effect we observed in t
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patients with cardiovascular disease was in the 
 direction favouring liberal transfusion, but without 
statistical significance (1.10, 0.84 to 1.44). We specifi-
cally excluded trials in cardiac surgery as this is com-
prises a distinct group of patients with a cardiovascular 
risk that has been altered profoundly by their proce-
dure. A recent large multicentre randomised controlled 
trial in cardiac surgery74  found no difference in a com-
posite morbidity outcome, but the 90 day mortality rate 
was significantly higher in the restrictive transfusion 
group compared with liberal transfusion group. A 
recent systematic review and meta-analysis restricted 
to trials in cardiac surgery also found increased mortal-
ity with restrictive transfusion thresholds.18  Another 
systematic review75 of perioperative randomised con-
trolled trials of transfusion practice (including cardiac 
surgery) also found higher mortality with a restrictive 
transfusion threshold, although the prevalence of car-
diovascular disease in these trials was uncertain. 
These data suggest that the presence of cardiovascular 
disease may modify the effect of transfusion practice 
on clinical outcomes considerably, and the data high-
light the need for better evidence for this prevalent 
patient group.
We found that new onset acute coronary syndrome 
occurred more often with restrictive transfusion strate-
gies. The pooled estimates were 2.7% for liberal transfu-
sion compared with 4.6% for restrictive transfusion 
(number needed to treat approximately 52 to prevent an 
acute coronary syndrome with more liberal transfu-
sion). The variation in patient populations, transfusion 
strategies compared, and method of ascertaining acute 
coronary syndrome create substantial uncertainty in 
these estimates, but the heterogeneity between trials 
was low. The estimate of effect was the same when the 
largest trial was removed. Importantly, for most 
included cases the restrictive transfusion threshold was 
80 g/L compared with a liberal transfusion threshold of 
100 g/L. These findings suggest that a transfusion 
threshold of 70 g/L, which is widely recommended as 
the “default” threshold, may not be as safe as higher 
thresholds for preventing acute coronary syndrome in 
patients with cardiovascular disease. The safest haemo-
globin threshold is uncertain and may be patient spe-
cific, but we have shown potential for harm with 
restrictive triggers less than 80 g/L. Further trials are 
needed to inform the optimal transfusion strategy in 
patients with cardiovascular disease. Myocardial injury 
Myocardial infarction, acute coronary syndrome, cardiac arrest
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Total
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Not estimable
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Fig 3 | Forest plot showing risk ratios for adverse cardiovascular events and risk of bias assessment for each study
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could have an effect on other important clinical out-
comes such as length of hospital stay, quality of life, 
longer term mortality, and healthcare costs, but few tri-
als have measured these outcomes. These outcomes, 
together with cost effectiveness, should be included in 
future research, particularly as the cost of blood trans-
fusions is relatively low and even in the liberal transfu-
sion arm in this review patients typically received only 
two or three units. Our review highlights the variability 
in diagnostic definitions of acute coronary syndrome 
and the potential for ascertainment bias in clinical tri-
als where blinding of intervention groups is difficult. 
This resulted in low evidence of quality according to 
GRADE, and it highlights the need for further high qual-
ity research.
We found no effect on acute pulmonary oedema, but 
the numbers of trials and patients in whom this out-
come was reported was small and the findings were 
heterogeneous. Acute pulmonary oedema can result 
from multiple causes, including transfusion associated 
circulatory overload, and the potential for an effect in a 
different direction from acute coronary syndrome 
made it important to consider these outcomes sepa-
rately rather than to include them as a composite. 
Future trials should standardise diagnostic methods 
for both acute coronary syndrome and acute pulmo-
nary oedema and attempt to blind outcome assessors 
to group allocation.
limitations of this review
Our review has several limitations. There was clinical 
diversity between trial populations—for example, 
between orthopaedic surgery and critical care. The 
risk-benefit balance may vary between clinical situa-
tions (for example, as a result of the degree and dura-
tion of physiological stress). The restrictive and liberal 
transfusion thresholds varied between trials, and the 
cut-off values actually overlapped (restrictive threshold 
70-97 g/L; liberal threshold 90-113 g/L), which reduces 
the validity of pooling data across all trials. Exposure to 
anaemia would have been considerably longer in the 
four intensive care unit trials than in the four surgical 
trials, in which the presence of anaemia would have 
been relatively short. Definitions of cardiovascular dis-
ease varied, and inclusion criteria for some trials were 
restricted to ischaemic heart disease or acute coronary 
syndrome. However, the direction of effect was consis-
tently in favour of a liberal transfusion threshold for 
reducing new acute coronary syndrome events across 
the trials. Finally, some authors did not respond to our 
request for data on their participants with cardiovascu-
lar disease, and this reduced the precision of our point 
estimates.
Conclusion
This review of available evidence suggests that for 
anaemic patients with cardiovascular disease, the use 
of restrictive transfusion thresholds (typically a hae-
moglobin level of 70-80 g/L) is associated with higher 
rates of acute coronary syndrome than more liberal 
transfusion thresholds (typically 90-100 g/L). No 
effects on mortality or other important outcomes were 
found. The currently available quality of evidence for 
all outcomes was low. These data support the use of a 
more liberal transfusion threshold (>80 g/L) for 
patients with both acute and chronic cardiovascular 
disease, until adequately powered high quality ran-
domised trials have been undertaken in this patient 
population.
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